

Opportunities and challenges for the application of microfluidic technologies in point-of-care veterinary diagnostics

Citation for published version:

Busin, V, Wells, B, Kersaudy-Kerhoas, M, Shu, W & Burgess, STG 2016, 'Opportunities and challenges for the application of microfluidic technologies in point-of-care veterinary diagnostics', *Molecular and Cellular Probes*, vol. 30, no. 5, pp. 331–341. <https://doi.org/10.1016/j.mcp.2016.07.004>

Digital Object Identifier (DOI):

[10.1016/j.mcp.2016.07.004](https://doi.org/10.1016/j.mcp.2016.07.004)

Link:

[Link to publication record in Heriot-Watt Research Portal](#)

Document Version:

Peer reviewed version

Published In:

Molecular and Cellular Probes

General rights

Copyright for the publications made accessible via Heriot-Watt Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.


Take down policy

Heriot-Watt University has made every reasonable effort to ensure that the content in Heriot-Watt Research Portal complies with UK legislation. If you believe that the public display of this file breaches copyright please contact open.access@hw.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Opportunities and challenges for the application of microfluidic technologies in point-of-care veterinary diagnostics

Valentina Busin, Beth Wells, Maiwenn Kersaudy-Kerhoas, Wenmaio Shu, Stewart T.G. Burgess



PII: S0890-8508(16)30049-4

DOI: [10.1016/j.mcp.2016.07.004](https://doi.org/10.1016/j.mcp.2016.07.004)

Reference: YMCPR 1225

To appear in: *Molecular and Cellular Probes*

Received Date: 31 March 2016

Revised Date: 14 July 2016

Accepted Date: 14 July 2016

Please cite this article as: Busin V, Wells B, Kersaudy-Kerhoas M, Shu W, Burgess STG, Opportunities and challenges for the application of microfluidic technologies in point-of-care veterinary diagnostics, *Molecular and Cellular Probes* (2016), doi: 10.1016/j.mcp.2016.07.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Opportunities and challenges for the application of microfluidic technologies in point-of-care veterinary diagnostics

Valentina Busin^{a,b*}, Beth Wells^a, Maïwenn Kersaudy-Kerhoas^b, Wenmaio Shu^{b,c} and Stewart T. G. Burgess^a

^a*Moredun Research Institute, Pentlands Science Park, Bush Loan, Edinburgh. EH26 0PZ. United Kingdom.*

^b*School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh. EH14 4AS. United Kingdom.*

^c*Department of Biomedical Engineering, University of Strathclyde, Glasgow. G4 0NW. United Kingdom*

*Corresponding author. Moredun Research Institute, Pentlands Science Park, Bush Loan, Edinburgh. EH26 0PZ. United Kingdom. Email: valentina.busin@moredun.ac.uk (V. Busin).

Email addresses:

VB: valentina.busin@moredun.ac.uk

BW: beth.wells@moredun.ac.uk

MKK: m.kersaudy-kerhoas@hw.ac.uk

WS: will.shu@strath.ac.uk

STGB: stewart.burgess@moredun.ac.uk

Abstract

There is a growing need for low-cost, rapid and reliable diagnostic results in veterinary medicine. Point-of-care (POC) tests have tremendous advantages over existing laboratory-based tests, due to their intrinsic low-cost and rapidity. A considerable number of POC tests are presently available, mostly in dipstick or lateral flow formats, allowing cost-effective and decentralised diagnosis of a wide range of infectious diseases and public health related threats. Although, extremely useful, these tests come with some limitations. Recent advances in the field of microfluidics have brought about new and exciting opportunities for human health diagnostics, and there is now great potential for these new technologies to be applied in the field of veterinary diagnostics. This review appraises currently available POC tests in veterinary medicine, taking into consideration their usefulness and limitations, whilst exploring possible applications for new and emerging technologies, in order to widen and improve the range of POC tests available.

Keywords

Point-of-care, veterinary diagnostics, microfluidics, lateral flow immunoassays, paper-based microfluidics, dipstick test.

1. Introduction

Point-of-care (POC) diagnostics is an area that has attracted considerable attention in the last decade. Testing at POC means that analytical procedures are carried out at the side of or near to the patient [1], for this reason, it is also sometimes referred to as “bed-side” testing [2]. The reasons for the considerable interest in the field of POC testing are numerous: the potential to decrease costs of diagnosis [3], increasing the accessibility of these types of test to disadvantaged populations [4], and reducing the time between sampling and a treatment decision [5].

Following the global trend towards more affordable and accessible diagnostic testing, the Sexually Transmitted Diseases Diagnostics Initiative (SDI) within the World Health Organization (WHO) recently established a set of benchmark criteria for the ideal rapid test, under the acronym “ASSURED” [6]: Affordable, Sensitive, Specific, User-friendly (simple to perform in a few steps, with minimal technical training), Robust and rapid (results available in less than 30 min), Equipment-free, Deliverable to those who need them. Ideally, POC tests should respect all or as many as possible of these characteristics [7].

2. Point of care testing and its scope in veterinary medicine

In the veterinary area, there is a similar need for low-cost, reliable and rapid diagnostic tests to be carried out at the POC [8]. So called on-site or animal-side tests will have considerable advantages over laboratory-based testing, which usually involves laborious and expensive laboratory techniques and dedicated technical personnel. All of the analytical processes involved in testing, from collection of the sample to communication of the results, could potentially be performed in a single step, considerably reducing the time between testing and treatment [9]. This can translate into more affordable veterinary care, reduced handling of animals, targeted treatments and rapid testing in more remote geographic areas.

The need for more affordable, rapid and accessible tests is a recurrent theme in the literature, in particular as an invaluable tool in dealing with diseases that either represent a threat to public health [10], have substantial impact on animal welfare [11] and/or are of economic importance [12], with particular

relevance to situations where laboratory facilities and funds are limited [13]. Furthermore, the general globalisation of trade of animals and animal products has greatly increased the risk of rapid and wide-ranging spread of emerging and exotic diseases, requiring timely and efficient ways of dealing with diseases that could have catastrophic repercussions for the individual farmer, as well as economic implications for the entire country and international trade [14]. In situations concerning disease outbreaks, where rapid propagation of infectious agents and/or high mortality are salient features, as in the case of the highly pathogenic H5N1 strain of avian influenza virus, a rapid “animal-side” test would represent a critical tool for both collecting surveillance data and for assisting in the control of outbreaks [11, 15]. Currently available veterinary POC tests offer a good opportunity for a truly “animal-side” diagnosis, but the analytical performances of “on-site” testing are still considered limited compared with laboratory-based testing [16], whilst the possibility offered by the support of a central laboratory in the interpretation of the results is still perceived as critical [17]. Recent advances in microfluidic technologies for POC testing in the human field could overcome these hurdles and might be applied in veterinary medicine. This review aims to appraise the current status of POC testing in veterinary medicine, describing their advantages and limitations, whilst also assessing the potential of microfluidic technologies to improve existing POC tests and solve some of their intrinsic limitations.

3. Point-of-care devices currently available in veterinary diagnostics

At present, the most widely used technologies for POC testing in veterinary medicine are: dipstick tests and lateral flow immunoassays.

3.1 Dipstick and strip test

These assays are based on the principle of immunoblotting and are made of paper strips with pads to analyse specific fluids. After the sample is introduced, the results are compared with a colour-coded chart to provide a semi-quantitative determination of the analyte(s). The most commonly used are test strips

developed for human urine analysis, allowing the simultaneous detection or monitoring of leukocytes, nitrite, urobilinogen, protein, pH, haemoglobin, specific gravity, ketones, bilirubin and/or glucose (Fig. 1) [18]. While it has been developed for human patients, there is a high correlation between the dipstick results and other routinely used methods for urine analysis, which has resulted in this test being widely used in small animal private practice for first-line diagnosis of chronic kidney disease, mainly through an assessment of proteinuria [19, 20]. However, care should be taken when interpreting positive test results with low levels of proteins (traces) due to the high rate of false positive results [21].

A smaller version of the urine dipstick, restricted to detection of glucose and ketone bodies, is also largely applied for at-home management of pets with diabetes. This test is also widely used in farmed ruminants for the diagnosis of ketosis in cattle [22] and pregnancy toxaemia in sheep. Due to some variation in results, a further advance in the diagnosis of these diseases is the use of appropriate strips combined with electronic hand-held meters to accurately measure both glucose and one of the main ketone bodies, β -hydroxybutyrate (BHB) in blood, making diagnosis more reliable as well as sampling potentially more successful and less stressful [23]. This POC test has shown great potential for the quantitative detection of BHB, with improved sensitivity and specificity when compared with dipstick tests for detection of ketones in urine or milk [24, 25]. Its use for glucose measurement, however, does not seem to be reliable [23]. Dipstick tests have also been used for the detection of antibiotics in serum, milk and/or meat samples [26]. These rapid tests allow the detection of antibiotics within the $\mu\text{g/ml}$ range, permitting on-site monitoring of non-authorised uses of antimicrobials, which could be especially useful in slaughterhouses and food processing plants.

The main advantage of these POC tests is that they can be readily carried out by the owners, proving to be particularly useful for the long term management of chronic diseases [27]. The major limitation, however, can be the subjective interpretation of results, based on a personal evaluation of a colorimetric reaction [19].

3.2 Lateral flow immunoassays (LFIAs)

These devices are based on the principle of capillary force: a liquid flowing on or through a strip of polymeric material, on or in which specific molecules (e.g., antigens, antibodies, DNA/RNA sequence) have been immobilized [28]. These strips usually consist of multiple pads: a sample application pad, a conjugate pad, a membrane for detection and an absorbent pad (Fig. 2), usually made of different materials (e.g., nitrocellulose, glass fibre paper and fused silica) encased in a plastic cage for protection of a fragile paper membrane [29]. The best known example of a lateral flow test is the pregnancy test [30], which is probably the most used POC test worldwide. The main advantages of lateral flow over traditional laboratory-based tests are their simplicity, rapidity and low cost. Compared with traditional laboratory-based tests, LFIAs are considerably less expensive, but, due to the different materials required, they are still relatively costly (~\$10 for a pregnancy test; [29]) for application in low-resource settings [31], and, due to the multi step processes involved, manufacturing time is extended, making them less suitable for high-throughput production.

They usually provide a qualitative or semi-quantitative result, and analytical performance is generally poorer than laboratory-based tests, mainly due to reduced sensitivity [32, 33] and the possibility of errors due to testing by untrained personnel [2]. When compared with reference laboratory tests, specificity tends to be comparable, while sensitivity can be as low as 16%, suggesting that a positive result might be trusted, whereas, in the case of negative results, further confirmatory laboratory testing may be advisable. Several studies have assessed quantitation, but such devices still require instrumentation [34, 35] and trained personnel, and are still limited to single analyte testing.

3.2.1 *Companion animals*

There is a significant market for the use of LFIAs for a range of acute and chronic diseases or conditions in companion animals (Table 1). These assays are usually easy to perform and interpret [32], with the possibility to improve sensitivity by using a dedicated LFIA reader, which allows an objective and quantitative interpretation of the results [28]. Although the cost of the test is an important consideration, reduced waiting time and the possibility of starting a therapy within the first visit are amongst the main

advantages of tests that can be carried out “in-house”. It is also important to consider that some diseases have received considerably greater attention, notably viral infection diseases, such as FIV and FeLV in cats and parvovirus in dogs, with an extended range of assays being available.

3.2.2 *Livestock*

For livestock, LFIAAs have been focused mainly on illnesses that represent a substantial economic burden and/or serious zoonotic or epidemic diseases (Table 2). OIE-listed diseases of the World Organization for Animal Health, such as Foot-and-Mouth Disease (FMD) and Rinderpest have received considerable attention, due to the crucial importance of a rapid diagnosis and, consequently, prompt intervention from veterinary authorities. In the case of FMD, endemic areas are frequently in developing countries, and often diagnosis is not reached due to the prolonged time between collection of samples, arrival at the reference laboratory and subsequent testing [36]. In this case, both the economic constraints and accessibility to remote areas are the dominant issues.

3.2.3 *Food safety*

Lateral flow tests have been successfully applied in two main areas: the detection of food-borne pathogens and the detection of fraudulent substances in animal feed or in animal products (Table 3). In the first case, much emphasis is placed on the prevention of zoonotic diseases, which represent a significant and widespread public health threat. In the second case, recent feed-stuff scandals [37, 38] and increasing reports of antimicrobial resistance dominate the scene, both in terms of research and public attention. Here, and on-site test can be a powerful tool for rapid detection and subsequent surveillance, especially when dealing with highly perishable products.

4. **Microfluidic technologies available for POC diagnostics**

One of the most promising technologies that has been applied recently in diagnostics is microfluidics, which involves the analysis of extremely small amounts (microlitres or nanolitres) of fluid using interconnected networks of channels measuring tens to hundreds of micrometres [39]. Since the introduction of microfluidics from the early 1990s [40], there has been a constant evolution of these methods, mainly following critical advances in microfabrication technologies [41]. Fluid transport in these devices is achieved by either passive (usually capillary forces) or active (generally pumping) mechanisms [42, 43], with the fluid flow being typically laminar [44].

Among the main advantages of microfluidics technologies for diagnostic applications are their portability and their low consumption of reagents; these attributes have made these devices inexpensive, rapid and generally easier to use compared with conventional (macroscale) testing [45]. The use of very small volumes, associated with shorter diffusional distances, results in significantly reduced time for analysis, making microfluidic assays significantly more rapid to perform than their macroscale equivalents [46]. Furthermore, being able to perform all necessary steps within one device and potentially in a single reaction represent a considerable advantage, allowing sample pre-treatment, analysis, signal detection and amplification in the same device [47]. Automated control of all steps can reduce inherent human error, which in turn increases the quality, reproducibility and reliability of assay results. The higher degree of control of fluid flow and the timing of binding reactions can also result in significantly improved analytical performance [48], while the opportunity for tests to be carried out simultaneously offers considerable potential for multiplexing [47]. Examples of the successful applications of these new technologies are in the clinical analysis of blood [49-51], pathogen identification [52, 53], genetic testing [54, 55], detection of environmental contaminants [56] and for drug screening [57].

Currently, two main types of microfluidic systems are used in the diagnostic field: micro total analysis systems (μ TAS) and microfluidic paper-based analytical devices (μ PADs). However, to date, there has been very limited application of this technology in the veterinary field [58].

4.1 *Micro total analysis systems (μ TAS)*

These systems are also commonly known as “lab on a chip” (LOC) devices (Fig. 3), which use fluid as a working medium and can integrate a number of different functionalities on a micro scale [41]. One of the main advantages of μ TAS devices is that they allow for all steps (from sample pre-treatment to signal detection) to be carried out at once, on the same device, allowing complicated molecular techniques (i.e. polymerase chain reaction (PCR)) to be transferred on the chip for POC testing. These devices are fabricated using techniques from the microelectronics industry [59], mostly using materials, such as silicon, glass and/or polymers [60]. At present, the most common materials used are thermoplastic polymers. These devices have reduced production costs, and have suitable mechanical, chemical and thermal properties [61].

Their diagnostic use is well established, with companies already commercialising POC devices on plastic platforms [62]. In the last decade, there has been a considerable focus on immunodiagnostic tests for the detection of disease markers, specifically for cardiac and cancer markers [63-66] and for the diagnosis of infectious diseases, including HIV/AIDS [67, 68], influenza [69] and hepatitis [70]. Some limitations of these devices are inherent in physical effects, such as the need for pressure-driven liquid flow, with the possible consequence of heat generation and, therefore, detrimental effects on biomolecules, or low grade mass transfer and/or reduced mixing capacity [41].

4.2 Microfluidic paper-based analytical devices (μ PADs)

These devices are commonly referred to as paper-based microfluidics (Fig. 4), a concept that was first introduced by the Whiteside group at Harvard University, following on from initial research performed on paper strips for the determination of pH [71]. These devices allow inexpensive multiplexed analyses to be carried out [72], while maintaining the advantages of conventional microfluidic technology, such as size, speed and reduced sample volumes [7]. Paper has considerable advantages over other materials in that it is cheap, easy to source, biodegradable and naturally abundant, but also simple to modify chemically [73]. POC devices made from paper also have the advantage of not requiring external power sources, whilst fabrication techniques and machinery for production are usually less expensive than those for other

materials, with minimal technical expertise required [74]. Paper represents an excellent medium for diagnostic testing, due to its high surface to volume ratio, which allows reagents to be concentrated, enabling more rapid reaction times [75]. Although μ TAS are renowned for being less expensive than conventional laboratory-based testing, materials such as glass and silicon can still be considered expensive, either in terms of their environmental footprint or in their production costs [47]. Therefore, one of the main advantages of choosing μ PADs over μ TAS as a diagnostic platform is their reduced cost. Also μ PADs are considered to be “easier” to produce, with no requirement for valves or pumps, as they use capillary force to move fluids within the device [74]; however, there can be issues with sample retention and evaporation, making them less suited to the analysis of small volumes [76].

5. Possible applications of microfluidic technologies in veterinary medicine

POC is already widely applied in veterinary medicine, and new and emerging technologies could bring substantial improvements to both the range of tests available and their inherent performance. The reduction in cost and time coupled to the possibility of multiplexing and one-step applications make these devices attractive for cost-effective and on-site testing of animals. Although microfluidics are, at the moment, predominantly applied to human diagnostics (Table 4), there have been examples of applications to areas of veterinary interest [77-81]. Microfluidic platforms have been successfully used for detection of food-borne pathogens, such as *Escherichia coli* O157:H7, *Listeria monocytogenes* and *Salmonella typhimurium* [82] as well as for detection of progesterone in serum samples [83]. The use of microfluidics has also been applied to improve the range of existing POC tests available for the detection of subclinical ketosis in cattle [84], in particular, by allowing on farm testing of samples such as milk.

5.1 Nucleic acid amplification

Combining nucleic acid amplification techniques with microfluidic technologies to detect low concentrations of molecules in a rapid, reliable and economical way represents an opportunity for new POC

technologies. The most widely used amplification technique is PCR [85], which is often used for infectious disease diagnosis, especially for the detection of small amounts of pathogen DNA. A possible limitation of laboratory-based PCR techniques is their cost, and the time and expertise required for testing. A promising application of microfluidics is DNA amplification on silicon chips [86], although the need for a thermocycler limits its application in the field. For this reason, new amplification technologies, based on isothermal nucleic acid amplification have received considerable attention, and appear to allow for improvement of assay sensitivity, while providing a rapid and cost-effective approach [87]. Examples of the integration of this method into μ TAS devices are growing [88-91], with existing applications to the detection of pathogens of veterinary importance, such as *Cryptosporidium parvum* [92, 93], *E. coli* [94], *Salmonella typhimurium* [77, 95] and *Suid herpesvirus 1* [96].

5.2 Multiplexing

A significant benefit of microfluidic technologies is the possibility to perform different tests in or on the same device [97]. Multiplexing has particular relevance in situations where multiple agents are involved [98] or where clinical signs are similar between/among distinct diseases [99, 100]. In this case, a POC “package” could be offered, in order to screen a single sample for all key pathogens involved in a particular disease scenario or complex [101, 102]. Other advantages could be the parallel interpretation of different tests for the same condition, in order to significantly increase test sensitivity [103] and the analysis of multiple markers to specifically diagnose a disease or condition, especially in the case of a progressive disease; or for monitoring therapeutic effectiveness. Finally, performing multiple tests at once, can also result in a reduction in cost, time and sample use [104].

5.3 Telemedicine and surveillance

Perhaps the most important advance in diagnostics is the possibility of combining microfluidics technologies with mobile read outs and electronic data storage. Since mobile phones have become

household items across the world and smart-phone cameras are of a high quality [105], the combination of these technologies could truly represent the future for POC. Examples of mobile read out and telemedicine applied to microfluidics are increasing [106-109], and show great promise. They allow for remote and cost efficient diagnosis, and also for information to be stored and shared automatically, making the process time-efficient and reducing human error [110]. At the same time, animal tracking systems are becoming automated, with widespread use of electronic identification, in the format of microchips and electronic ear tags/boluses. From the veterinary perspective, exploiting the opportunities of “distance-diagnosis” with efficient animal tracking could have a tremendous impact on disease control and surveillance, with considerable advantages for the monitoring of notifiable and zoonotic diseases, as in the case of bovine spongiform encephalopathy (BSE) [111] and in screening for changes in disease patterns [112]. Surveillance schemes are mostly carried out by official laboratories at considerable cost [113]. Recent restructuring of some diagnostic services will inevitably have a significant impact on diagnostic capability [114], which means that the present scanning surveillance systems may not be sustainable in the long term, such that alternative options might be required.

5.4 Disposal and handling of biological material

One of the main advantages of microfluidic devices is the possibility for the safe disposal of biological material [115]. This is of particular relevance for paper, where disposal of bio-hazardous waste could be safely and quickly achieved by incineration [116]. The advantages are in the further reduction of waste management costs, but, more importantly in the reduced risks of handling biological samples that might represent a health and safety risk [117]. It has been shown that veterinary surgeons are often concerned about the health and safety of packaging samples entering the postal system, as they are responsible for proper packaging and the safety of the recipient [17]. Therefore, safe and low-cost disposal of potentially bio-hazardous material represents a substantial added benefit for these new technologies.

6. Challenges

320

321 One of the biggest challenges in the field of microfluidics is the translation from academic research to
322 end-user products [118]. While the field of microfluidics has seen an exponential development in recent
323 years, the launch of a commercialised platform that would revolutionise the concept of microfluidic
324 technologies is still lacking [119]. Something similar to the breakthrough achieved by the pregnancy test
325 may be required to enable microfluidics-based testing to be more widely accepted. Unfortunately, the fact
326 that the diagnostic field is already quite mature, makes it harder to find companies willing to invest in new
327 areas [116], and the difficulties in changing people's attitudes toward testing can represent an additional
328 hurdle, especially when methods have been in place for many years. In this respect, the perception that
329 analytical performances are still inferior to traditional laboratory-based tests remains a considerable
330 constraint to the uptake of these technologies [2]. However, there is evidence that when a rapid result can
331 achieve a better treatment rate, the sensitivity of a test can play a less important role [120]. This situation
332 is extremely applicable in the veterinary field, where owners may struggle to find time for follow up visits
333 after a test has been performed, or it may be problematic for farmers to re-gather animals days after
334 testing [121]. Furthermore, as already in place for instrumental veterinary POC testing [122], specific
335 guidelines should be put in place for the quality assurance of newly developed POCs, in order to provide a
336 consistent and practical approach to evaluating their performance and increasing veterinarians' confidence
337 in test results [123].

338 While some of the challenges faced in human healthcare have been addressed by the use of microfluidic
339 technologies, this is not the case for animal health-related areas. For example, although the use of
340 microfluidic technologies is suited for telemedicine, the handling or recording of data needs to be carefully
341 organised. Data management systems are available for POC [124], which allow for valuable information to
342 be stored and made available in real time. However, in the case of notifiable diseases, specific rules and
343 strict controls will be required to ensure that legislation is followed. Another significant challenge will be
344 the need for targeted solutions according to the specific situation, remembering that a beloved sick
345 companion animal will require a different approach from livestock displaying signs of a potentially zoonotic
346 disease.

Finally, in order to fully exploit the potential of the new technologies at the POC, a higher degree of collaboration between engineers and biologists is required. Whilst, at the moment, the majority of the publications regarding microfluidics are in engineering journals [125], increasing publication of these topics in biological journals would help overcome some of the existing barriers. From an engineering point of view, research may focus predominantly on resolving the physical and chemical barriers posed by microfluidic technologies, while, from a veterinary diagnostics perspective, practical solutions are the main focus. By facilitating better communication between technology designers and end-users, a truly interdisciplinary approach could be achieved, which will help to solve the issue of translation of these technologies to the veterinary field.

7. Conclusions

Considering the wide array of veterinary conditions and the nature of veterinary diagnostics, POC testing offers distinct advantages over traditional laboratory-based testing. The advent of microfluidic technologies has further increased the opportunities for wider and more valuable use of POC testing. Although these technologies have not yet been applied as widely to veterinary medicine as they have in human medicine, they still offer great potential. Many of the hurdles encountered in diagnostics are commonly shared in human and animal medicine; advances in one field will therefore provide benefits to both sides, as long as specific needs faced from an animal health point of view are kept in mind. Importantly, a close collaboration between engineers, developing new and existing technologies and those at the end point in need of improved solutions will be of paramount importance.

Acknowledgements

The authors would like to thank Moredun Scientific Ltd. and Heriot-Watt University for generously funding this research.

References

- [1] P. St-Louis, Status of point-of-care testing: Promise, realities, and possibilities, *Clin. Biochem.* 33 (2000) 427-440.
- [2] P. von Lode, Point-of-care immunotesting: Approaching the analytical performance of central laboratory methods, *Clin. Biochem.* 38 (2005) 591-606.
- [3] K. Foster, G. Despotis, M.G. Scott, Point-of-care testing - Cost issues and impact on hospital operations, *Clin. Lab. Med.* 21 (2001) 269-284.
- [4] D. Mabey, R.W. Peeling, A. Ustianowski, M.D. Perkins, Diagnostics for the developing world, *Nat. Rev. Microbiol.* 2 (2004) 231-240.
- [5] N.-E. Drenck, Point of care testing in Critical Care Medicine: the clinician's view, *Clin. Chim. Acta* 307 (2001) 3-7.
- [6] R.W. Peeling, K.K. Holmes, D. Mabey, A. Ronald, Rapid tests for sexually transmitted infections (STIs): the way forward, *Sex. Transm. Infect.* 82 (2006) V1-V6.
- [7] C. Rozand, Paper-based analytical devices for point-of-care infectious disease testing, *Eur. J. Clin. Microbiol.* 33 (2013) 147-156.
- [8] E. Bollo, Nanotechnologies applied to veterinary diagnostics, *Vet. Res. Commun.* 31 (2007) 145-147.
- [9] G.J. Kost, Guidelines for point-of-care testing. Improving patient outcomes, *Am. J. Clin. Pathol.* 104 (1995) S111-S127.
- [10] G.K. Adak, S.M. Long, S.J. O'Brien, Trends in indigenous foodborne disease and deaths, England and Wales: 1992 to 2000, *Gut* 51 (2002) 832-841.
- [11] K. Chen, W. He, H. Lu, D. Song, W. Gao, Y. Lan, et al., Development of an Immunochromatographic Strip for Serological Diagnosis of Porcine Hemagglutinating Encephalomyelitis Virus, *J. Vet. Diagn. Invest.* 23 (2011) 288-296.
- [12] S.J. Cui, S.H. Zhou, C.M. Chen, T. Qi, C.F. Zhang, J. Oh, A simple and rapid immunochromatographic strip test for detecting antibody to porcine reproductive and respiratory syndrome virus, *J. Virol. Methods* 152 (2008) 38-42.
- [13] A.C. Banyard, D.L. Horton, C. Freuling, T. Muller, A.R. Fooks, Control and prevention of canine rabies: The need for building laboratory-based surveillance capacity, *Antiviral Res.* 98 (2013) 357-364.
- [14] K.S. Howe, B. Hasler, K.D.C. Stark, Economic principles for resource allocation decisions at national level to mitigate the effects of disease in farm animal populations, *Epidemiol. Infect.* 141 (2013) 91-101.
- [15] A. Abd El Wahed, A. El-Deeb, M. El-Tholoth, H. Abd El Kader, A. Ahmed, S. Hassan, et al., A Portable Reverse Transcription Recombinase Polymerase Amplification Assay for Rapid Detection of Foot-and-Mouth Disease Virus, *PLoS One* 8 (2013) e71642.
- [16] C.G. Fraser, Optimal analytical performance for point of care testing, *Clin. Chim. Acta* 307 (2001) 37-43.

- 408 [17] P.A. Robinson, W.B. Epperson, Farm animal practitioners' views on their use and expectations of
409 veterinary diagnostic laboratories, *Vet. Rec.* 172 (2013) 503-508.
- 410 [18] B.C. Smith, M.J. Peake, C.G. Fraser, Urinalysis by use of multi-test reagent strips: 2 dipsticks compared,
411 *Clin. Chem.* 23 (1977) 2337-2340.
- 412 [19] B.C. Garner, C.E. Wiedmeyer, Comparison of a semiquantitative point-of-care assay for the detection
413 of canine microalbuminuria with routine semiquantitative methods for proteinuria, *Vet. Clin. Pathol.* 36
414 (2007) 240-244.
- 415 [20] A. Zatelli, S. Paltrinieri, F. Nizi, X. Roura, E. Zini, Evaluation of a urine dipstick test for confirmation or
416 exclusion of proteinuria in dogs, *Am. J. Vet. Res.* 71 (2010) 235-240.
- 417 [21] S.D. Lyon, M.W. Sanderson, S.L. Vaden, M.R. Lappin, W.A. Jensen, G.F. Grauer, Comparison of urine
418 dipstick, sulfosalicylic acid, urine protein-to-creatinine ratio, and species-specific ELISA methods for
419 detection of albumin in urine samples of cats and dogs, *J. Am. Vet. Med. Assoc.* 236 (2010) 874-879.
- 420 [22] G.R. Oetzel, Monitoring and testing dairy herds for metabolic disease, *Vet. Clin. N. Am. - Food A.* 20
421 (2004) 651-674.
- 422 [23] K.J. Hornig, S.R. Byers, R.J. Callan, T. Holt, M. Field, H. Han, Evaluation of a point-of-care glucose and
423 beta-hydroxybutyrate meter operated in various environmental conditions in prepartum and postpartum
424 sheep, *Am. J. Vet. Res.* 74 (2013) 1059-1065.
- 425 [24] M. Iwersen, U. Falkenberg, R. Voigtsberger, D. Forderung, W. Heuwieser, Evaluation of an electronic
426 cowside test to detect subclinical ketosis in dairy cows, *J. Dairy Sci.* 92 (2009) 2618-2624.
- 427 [25] N. Panousis, C. Brozos, I. Karagiannis, N.D. Giadinis, S. Lafi, M. Kritsepi-Konstantinou, Evaluation of
428 Precision Xceed (R) meter for on-site monitoring of blood beta-hydroxybutyric acid and glucose
429 concentrations in dairy sheep, *Res. Vet. Sci.* 93 (2012) 435-439.
- 430 [26] N. Link, W. Weber, M. Fussenegger, A novel generic dipstick-based technology for rapid and precise
431 detection of tetracycline, streptogramin and macrolide antibiotics in food samples, *J. Biotechnol.* 128 (2007)
432 668-680.
- 433 [27] A.N. Plotnick, D.S. Greco, Home management of cats and dogs with diabetes mellitus. Common
434 questions asked by veterinarians and clients, *Vet. Clin. N. Am. - Small* 25 (1995) 753-759.
- 435 [28] G.A. Posthuma-Trumpie, J. Korf, A. van Amerongen, Lateral flow (immuno) assay: its strengths,
436 weaknesses, opportunities and threats. A literature survey, *Anal. Bioanal. Chem.* 393 (2009) 569-582.
- 437 [29] K. Abe, K. Kotera, K. Suzuki, D. Citterio, Inkjet-printed paperfluidic immuno-chemical sensing device,
438 *Anal. Bioanal. Chem.* 398 (2010) 885-893.
- 439 [30] K. May, Home tests to monitor fertility, *Am. J. Obstet. Gynecol.* 165 (1991) 2000-2002.
- 440 [31] D.R. Ballerini, X. Li, W. Shen, Patterned paper and alternative materials as substrates for low-cost
441 microfluidic diagnostics, *Microfluid. Nanofluid.* 13 (2012) 769-787.
- 442 [32] S. Schmitz, C. Coenen, K. Matthias, T. Heinz-Jürgen, R. Neiger, Comparison of Three Rapid Commercial
443 Canine Parvovirus Antigen Detection Tests with Electron Microscopy and Polymerase Chain Reaction, *J. Vet.*
444 *Diagn. Invest.* 21 (2009) 344-345.
- 445 [33] Y. Al-Yousif, J. Anderson, C. Chard-Bergstrom, S. Kapil, Development, evaluation, and application of
446 lateral-flow immunoassay (immunochromatography) for detection of rotavirus in bovine fecal samples,
447 *Clin. Diagn. Lab. Immunol.* 9 (2002) 723-724.
- 448 [34] Y.Y. Lin, J. Wang, G.D. Liu, H. Wu, C.M. Wai, Y.H. Lin, A nanoparticle label/immunochromatographic
449 electrochemical biosensor for rapid and sensitive detection of prostate-specific antigen, *Biosens.*
450 *Bioelectron.* 23 (2008) 1659-1665.
- 451 [35] X. Mao, M. Baloda, A.S. Gurung, Y.H. Lin, G.D. Liu, Multiplex electrochemical immunoassay using gold
452 nanoparticle probes and immunochromatographic strips, *Electrochem. Commun.* 10 (2008) 1636-1640.

- 453 [36] N.P. Ferris, A. Nordengrahn, G.H. Hutchings, S.M. Reid, D.P. King, K. Ebert, et al., Development and
454 laboratory validation of a lateral flow device for the detection of foot-and-mouth disease virus in clinical
455 samples, *J. Virol. Methods* 155 (2009) 10-17.
- 456 [37] R.E. Baynes, J.E. Riviere, Risks associated with melamine and related triazine contamination of food,
457 *Emerg. Health Threats J.* 3 (2010) e5.
- 458 [38] P.J. O'Mahony, Finding horse meat in beef products-a global problem, *QJM-An Int. J. Med.* 106 (2013)
459 595-597.
- 460 [39] G.M. Whitesides, The origins and the future of microfluidics, *Nature* 442 (2006) 368-373.
- 461 [40] A. Manz, N. Graber, H.M. Widmer, Miniaturized total chemical-analysis systems. A novel concept for
462 chemical sensing, *Sens. Actuator B-Chem.* 1 (1990) 244-248.
- 463 [41] S. Hardt, F. Schönfeld, *Microfluidic Technologies for Miniaturized Analysis Systems*, Springer, New
464 York, 2007.
- 465 [42] D. Juncker, H. Schmid, U. Drechsler, H. Wolf, M. Wolf, B. Michel, et al., Autonomous microfluidic
466 capillary system, *Anal. Chem.* 74 (2002) 6139-6144.
- 467 [43] D.J. Laser, J.G. Santiago, A review of micropumps, *J. Micromech. Microeng.* 14 (2004) R35-R64.
- 468 [44] H.A. Stone, A.D. Stroock, A. Ajdari, Engineering flows in small devices: Microfluidics toward a lab-on-a-
469 chip, *Annu. Rev. Fluid Mech.* 36 (2004) 381-411.
- 470 [45] A. de Mello, Plastic fantastic?, *Lab Chip* 2 (2002) 31N-36N.
- 471 [46] S. Rattle, O. Hofmann, C.P. Price, L.J. Kricka, D. Wild, Lab-on-a-Chip, Micro- and Nanoscale
472 Immunoassay Systems, and Microarrays, in: D. Wild (Ed.), *The Immunoassay Handbook*, Elsevier, Oxford,
473 2013, pp. 175-202.
- 474 [47] C.D. Chin, V. Linder, S.K. Sia, Lab-on-a-chip devices for global health: Past studies and future
475 opportunities, *Lab Chip* 7 (2007) 41-57.
- 476 [48] L. Gervais, N. de Rooij, E. Delamarche, Microfluidic Chips for Point-of-Care Immunodiagnostics, *Adv.*
477 *Mater.* 23 (2011) H151-H176.
- 478 [49] M.S. Khan, G. Thouas, W. Shen, G. Whyte, G. Garnier, Paper Diagnostic for Instantaneous Blood Typing,
479 *Anal. Chem.* 82 (2010) 4158-4164.
- 480 [50] A. Floris, S. Staal, S. Lenk, E. Staijen, D. Kohlheyer, J. Eijkel, et al., A prefilled, ready-to-use
481 electrophoresis based lab-on-a-chip device for monitoring lithium in blood, *Lab Chip* 10 (2010) 1799-1806.
- 482 [51] I.K. Dimov, L. Basabe-Desmonts, J.L. Garcia-Cordero, B.M. Ross, A.J. Ricco, L.P. Lee, Stand-alone self-
483 powered integrated microfluidic blood analysis system (SIMBAS), *Lab Chip* 11 (2011) 845-850.
- 484 [52] N. Bunyakul, K.A. Edwards, C. Promptmas, A.J. Baeumner, Cholera toxin subunit B detection in
485 microfluidic devices, *Anal. Bioanal. Chem.* 393 (2009) 177-186.
- 486 [53] A.H. Diercks, A. Ozinsky, C.L. Hansen, J.M. Spotts, D.J. Rodriguez, A. Aderem, A microfluidic device for
487 multiplexed protein detection in nano-liter volumes, *Anal. Biochem.* 386 (2009) 30-35.
- 488 [54] A.J. Hopwood, C. Hurth, J.N. Yang, Z. Cai, N. Moran, J.G. Lee-Edghill, et al., Integrated Microfluidic
489 System for Rapid Forensic DNA Analysis: Sample Collection to DNA Profile, *Anal. Chem.* 82 (2010) 6991-
490 6999.
- 491 [55] L.L. Shui, J.G. Bomer, M.L. Jin, E.T. Carlen, A. van den Berg, Microfluidic DNA fragmentation for on-chip
492 genomic analysis, *Nanotechnology* 22 (2011).
- 493 [56] J.P. Lafleur, S. Senkbeil, T.G. Jensen, J.P. Kutter, Gold nanoparticle-based optical microfluidic sensors
494 for analysis of environmental pollutants, *Lab Chip* 12 (2012) 4651-4656.

- 495 [57] C. Liu, L. Wang, Z. Xu, J.M. Li, X.P. Ding, Q. Wang, et al., A multilayer microdevice for cell-based high-
496 throughput drug screening, *J. Micromech. Microeng.* 22 (2012).
- 497 [58] J.L. Garcia-Cordero, L.M. Barrett, R. O'Kennedy, A.J. Ricco, Microfluidic sedimentation cytometer for
498 milk quality and bovine mastitis monitoring, *Biomed. Microdevices* 12 (2010) 1051-1059.
- 499 [59] L.J. Kricka, Microchips, microarrays, biochips and nanochips: personal laboratories for the 21st century,
500 *Clin. Chim. Acta* 307 (2001) 219-223.
- 501 [60] P. Lisowski, P. Zarzycki, Microfluidic Paper-Based Analytical Devices (μ PADs) and Micro Total Analysis
502 Systems (μ TAS): Development, Applications and Future Trends, *Chromatographia* 76 (2013) 1201.
- 503 [61] P. Zhou, L. Young, Z.Y. Chen, Weak solvent based chip lamination and characterization of on-chip valve
504 and pump, *Biomed. Microdevices* 12 (2010) 821-832.
- 505 [62] W.K. Tomazelli Coltro, C.-M. Cheng, E. Carrilho, D.P. de Jesus, Recent advances in low-cost microfluidic
506 platforms for diagnostic applications, *Electrophoresis* 35 (2014) 2309-2324.
- 507 [63] S.S. Kallempudi, Z. Altintas, J.H. Niazi, Y. Gurbuz, A new microfluidics system with a hand-operated, on-
508 chip actuator for immunosensor applications, *Sensor. Actuat. B - Chem.* 163 (2012) 194-201.
- 509 [64] M.M. Caulum, B.M. Murphy, L.M. Ramsay, C.S. Henry, Detection of cardiac biomarkers using micellar
510 electrokinetic chromatography and a cleavable tag immunoassay, *Anal. Chem.* 79 (2007) 5249-5256.
- 511 [65] F. Darain, P. Yager, K.L. Gan, S.C. Tjin, On-chip detection of myoglobin based on fluorescence, *Biosens.*
512 *Bioelectron.* 24 (2009) 1744-1750.
- 513 [66] S.Q. Wang, X.H. Zhao, I. Khimji, R. Akbas, W.L. Qiu, D. Edwards, et al., Integration of cell phone imaging
514 with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care, *Lab Chip* 11
515 (2011) 3411-3418.
- 516 [67] X.H. Cheng, D. Irimia, M. Dixon, K. Sekine, U. Demirci, L. Zamir, et al., A microfluidic device for practical
517 label-free CD4+T cell counting of HIV-infected subjects, *Lab Chip* 7 (2007) 170-178.
- 518 [68] Y.-G. Kim, S. Moon, D.R. Kuritzkes, U. Demirci, Quantum dot-based HIV capture and imaging in a
519 microfluidic channel, *Biosens. Bioelectron.* 25 (2009) 253-258.
- 520 [69] B.S. Ferguson, S.F. Buchsbaum, T.-T. Wu, K. Hsieh, Y. Xiao, R. Sun, et al., Genetic Analysis of H1N1
521 Influenza Virus from Throat Swab Samples in a Microfluidic System for Point-of-Care Diagnostics, *J. Am.*
522 *Chem. Soc.* 133 (2011) 9129-9135.
- 523 [70] B.S. Lee, J.-N. Lee, J.-M. Park, J.-G. Lee, S. Kim, Y.-K. Cho, et al., A fully automated immunoassay from
524 whole blood on a disc, *Lab Chip* 9 (2009) 1548-1555.
- 525 [71] R.H. Muller, D.L. Clegg, Automatic paper chromatography, *Anal. Chem.* 21 (1949) 1123-1125.
- 526 [72] X. Li, D.R. Ballerini, W. Shen, A perspective on paper-based microfluidics: Current status and future
527 trends, *Biomicrofluidics* 6 (2012).
- 528 [73] W.A. Zhao, A. van den Berg, Lab on paper, *Lab Chip* 8 (2008) 1988-1991.
- 529 [74] A.W. Martinez, Microfluidic paper-based analytical devices: from POCKET to paper-based ELISA,
530 *Bioanalysis* 3 (2011) 2589-2592.
- 531 [75] E. Carrilho, S.T. Phillips, S.J. Vella, A.W. Martinez, G.M. Whitesides, Paper Microzone Plates, *Anal.*
532 *Chem.* 81 (2009) 5990-5998.
- 533 [76] J. Tian, D. Kannangara, X. Li, W. Shen, Capillary driven low-cost V-groove microfluidic device with high
534 sample transport efficiency, *Lab Chip* 10 (2010) 2258-2264.
- 535 [77] A.S. Patterson, D.M. Heithoff, B.S. Ferguson, H.T. Soh, M.J. Mahan, K.W. Plaxco, Microfluidic Chip-
536 Based Detection and Intraspecies Strain Discrimination of *Salmonella* Serovars Derived from Whole Blood
537 of Septic Mice, *Appl. Environ. Microbiol.* 79 (2013) 2302-2311.

- 538 [78] M. DiCicco, S. Neethirajan, An *in vitro* Microfluidic Gradient Generator Platform for Antimicrobial
539 Testing, *BioChip J.* 8 (2014) 282-288.
- 540 [79] J. Terry, S. Neethirajan, A novel microfluidic wound model for testing antimicrobial agents against
541 *Staphylococcus pseudintermedius* biofilms, *J. Nanobiotechnol.* 12 (2014).
- 542 [80] Y.Y. Dong, Y. Xu, Z.X. Liu, Y.F. Fu, T. Ohashi, Y. Tanaka, et al., Rapid screening swine foot-and-mouth
543 disease virus using micro-ELISA system, *Lab Chip* 11 (2011) 2153-2155.
- 544 [81] A. Wadhwa, R.S. Foote, R.W. Shaw, S. Eda, Bead-based microfluidic immunoassay for diagnosis of
545 Johne's disease, *J. Immunol. Methods* 382 (2012) 196-202.
- 546 [82] J.C. Jokerst, J.A. Adkins, B. Bisha, M.M. Mentele, L.D. Goodridge, C.S. Henry, Development of a Paper-
547 Based Analytical Device for Colorimetric Detection of Select Foodborne Pathogens, *Anal. Chem.* 84 (2012)
548 2900-2907.
- 549 [83] F.J. Arevalo, G.A. Messina, P.G. Molina, M.A. Zon, J. Raba, H. Fernandez, Determination of
550 progesterone (P4) from bovine serum samples using a microfluidic immunosensor system, *Talanta* 80
551 (2010) 1986-1992.
- 552 [84] X. Weng, L. Chen, S. Neethirajan, T. Duffield, Development of quantum dots-based biosensor towards
553 on-farm detection of subclinical ketosis, *Biosens. Bioelectron.* 72 (2015) 140-147.
- 554 [85] K.B. Mullis, F.A. Faloona, Specific synthesis of DNA *in vitro* via a polymerase-catalyzed chain-reaction,
555 *Method Enzymol.* 155 (1987) 335-350.
- 556 [86] J. Cheng, M.A. Shoffner, G.E. Hvhichia, L.J. Kricka, P. Wilding, Chip PCR .2. Investigation of different PCR
557 amplification systems in microfabricated silicon-glass chips, *Nucleic Acids Res.* 24 (1996) 380-385.
- 558 [87] C.C. Chang, C.C. Chen, S.C. Wei, H.H. Lu, Y.H. Liang, C.W. Lin, Diagnostic Devices for Isothermal Nucleic
559 Acid Amplification, *Sensors* 12 (2012) 8319-8337.
- 560 [88] X.Y. Zhao, T. Dong, Z.C. Yang, N. Pires, N. Hoivik, Compatible immuno-NASBA LOC device for
561 quantitative detection of waterborne pathogens: design and validation, *Lab Chip* 12 (2012) 602-612.
- 562 [89] L. Mahmoudian, J. Melin, M.R. Mohamadi, K. Yamada, M. Ohta, N. Kaji, et al., Microchip
563 electrophoresis for specific gene detection of the pathogenic bacteria *V-cholerae* by circle-to-circle
564 amplification, *Anal. Sci.* 24 (2008) 327-332.
- 565 [90] S.Y. Lee, C.N. Lee, H. Mark, D.R. Meldrum, C.W. Lin, Efficient, specific, compact hepatitis B diagnostic
566 device: Optical detection of the hepatitis B virus by isothermal amplification, *Sens. Actuator B-Chem.* 127
567 (2007) 598-605.
- 568 [91] E. Torres-Chavolla, E.C. Alocilja, Nanoparticle based DNA biosensor for tuberculosis detection using
569 thermophilic helicase-dependent isothermal amplification, *Biosens. Bioelectron.* 26 (2011) 4614-4618.
- 570 [92] M.B. Esch, L.E. Locascio, M.J. Tarlov, R.A. Durst, Detection of viable *Cryptosporidium parvum* using
571 DNA-modified liposomes in a microfluidic chip, *Anal. Chem.* 73 (2001) 2952-2958.
- 572 [93] H. Bridle, M. Kersaudy-Kerhoas, B. Miller, D. Gavrilidou, F. Katzer, E.A. Innes, et al., Detection of
573 *Cryptosporidium* in miniaturised fluidic devices, *Water Res.* 46 (2012) 1641-1661.
- 574 [94] I.K. Dimov, J.L. Garcia-Cordero, J. O'Grady, C.R. Poulsen, C. Viguier, L. Kent, et al., Integrated
575 microfluidic tmRNA purification and real-time NASBA device for molecular diagnostics, *Lab Chip* 8 (2008)
576 2071-2078.
- 577 [95] K. Sato, A. Tachihara, B. Renberg, K. Mawatari, Y. Tanaka, J. Jarvius, et al., Microbead-based rolling
578 circle amplification in a microchip for sensitive DNA detection, *Lab Chip* 10 (2010) 1262-1266.
- 579 [96] X.E. Fang, Y.Y. Liu, J.L. Kong, X.Y. Jiang, Loop-Mediated Isothermal Amplification Integrated on
580 Microfluidic Chips for Point-of-Care Quantitative Detection of Pathogens, *Anal. Chem.* 82 (2010) 3002-3006.

- [97] R.S. Sista, T. Wang, N. Wu, C. Graham, A. Eckhardt, T. Winger, et al., Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform, *Clin. Chim. Acta* 424 (2013) 12-18.
- [98] C. Tramuta, D. Lacerenza, S. Zoppi, M. Gorla, A. Dondo, E. Ferroglio, et al., Development of a set of multiplex standard polymerase chain reaction assays for the identification of infectious agents from aborted bovine clinical samples, *J. Vet. Diagn. Invest.* 23 (2011) 657-664.
- [99] G. Venkatesan, V. Balamurugan, V. Bhanuprakash, Multiplex PCR for simultaneous detection and differentiation of sheeppox, goatpox and orf viruses from clinical samples of sheep and goats, *J. Virol. Methods* 195 (2014) 1-8.
- [100] R.J. Lenhoff, P. Naraghi-Arani, J.B. Thissen, J. Olivas, A.C. Carillo, C. Chinn, et al., Multiplexed molecular assay for rapid exclusion of foot-and-mouth disease, *J. Virol. Methods* 153 (2008) 61-69.
- [101] R.W. Yousuf, A. Sen, B. Mondal, S.K. Biswas, K. Chand, K.K. Rajak, et al., Development of a single-plate combined indirect ELISA (CI-ELISA) for the detection of antibodies against peste-des-petits-ruminants and bluetongue viruses in goats, *Small Ruminant Res.* 124 (2015) 137-139.
- [102] Y.-I. Cho, D. Sun, V. Cooper, G. Dewell, K. Schwartz, K.-J. Yoon, Evaluation of a commercial rapid test kit for detecting bovine enteric pathogens in feces, *J. Vet. Diagn. Invest.* 24 (2012) 559-562.
- [103] S.L.B. McKenna, I.R. Dohoo, Using and interpreting diagnostic tests, *Vet. Clin. N. Am.-Food A. Practice* 22 (2006) 195-205.
- [104] J. Christopher-Hennings, K.P.C. Araujo, C.J.H. Souza, Y. Fang, S. Lawson, E.A. Nelson, et al., Opportunities for bead-based multiplex assays in veterinary diagnostic laboratories, *J. Vet. Diagn. Invest.* 25 (2013) 671-691.
- [105] A.W. Martinez, S.T. Phillips, E. Carrilho, S.W. Thomas, H. Sindi, G.M. Whitesides, Simple telemedicine for developing regions: Camera phones and paper-based microfluidic devices for real-time, off-site diagnosis, *Anal. Chem.* 80 (2008) 3699-3707.
- [106] A.F. Coskun, R. Nagi, K. Sadeghi, S. Phillips, A. Ozcan, Albumin testing in urine using a smart-phone, *Lab Chip* 13 (2013) 4231-4238.
- [107] J.L. Delaney, C.F. Hogan, J.F. Tian, W. Shen, Electrogenenerated Chemiluminescence Detection in Paper-Based Microfluidic Sensors, *Anal. Chem.* 83 (2011) 1300-1306.
- [108] B. Veigas, J.M. Jacob, M.N. Costa, D.S. Santos, M. Viveiros, J. Inacio, et al., Gold on paper-paper platform for Au-nanoprobe TB detection, *Lab Chip* 12 (2012) 4802-4808.
- [109] M. Funes-Huacca, A. Wu, E. Szepesvari, P. Rajendran, N. Kwan-Wong, A. Razgulin, et al., Portable self-contained cultures for phage and bacteria made of paper and tape, *Lab Chip* 12 (2012) 4269-4278.
- [110] C.D. Chin, Y.K. Cheung, T. Laksanasopin, M.M. Modena, S.Y. Chin, A.A. Sridhara, et al., Mobile Device for Disease Diagnosis and Data Tracking in Resource-Limited Settings, *Clin. Chem.* 59 (2013) 629-640.
- [111] C. Probst, J.M. Gethmann, R. Heuser, H. Niemann, F.J. Conraths, Direct Costs of Bovine Spongiform Encephalopathy Control Measures in Germany, *Zoonoses Public Health* 60 (2013) 577-595.
- [112] C. McMahon, A.W. Gordon, H.W.J. Edgar, R.E.B. Hanna, G.P. Brennan, I. Fairweather, The effects of climate change on ovine parasitic gastroenteritis determined using veterinary surveillance and meteorological data for Northern Ireland over the period 1999-2009, *Vet. Parasitol.* 190 (2012) 167-177.
- [113] J.A. Drewe, B. Hasler, J. Rushton, K.D.C. Stark, Assessing the expenditure distribution of animal health surveillance: the case of Great Britain, *Vet. Rec.* 174 (2014) 16-20.
- [114] A. Soldan, Changes to the VLA's diagnostic surveillance service, *Vet. Rec.* 167 (2010) 499-499.
- [115] M. Mahalanabis, J. Do, H. Almuayad, J.Y. Zhang, C.M. Klapperich, An integrated disposable device for DNA extraction and helicase dependent amplification, *Biomed. Microdevices* 12 (2010) 353-359.

- [116] A.K. Yetisen, M.S. Akram, C.R. Lowe, Paper-based microfluidic point-of-care diagnostic devices, *Lab Chip* 13 (2013) 2210-2251.
- [117] AHVLA censured for health and safety failings in handling samples, *Vet. Rec.* 172 (2013).
- [118] D. Mark, S. Haeberle, G. Roth, F. von Stetten, R. Zengerle, Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications, *Chem. Soc. Rev.* 39 (2010) 1153-1182.
- [119] H. Becker, Chips, money, industry, education and the "killer application", *Lab Chip* 9 (2009) 1659-1660.
- [120] T.L. Gift, M.S. Pate, E.W. Hook, W.J. Kassler, The rapid test paradox: When fewer cases defected lead to more cases treated - A decision analysis of tests for *Chlamydia trachomatis*, *Sex. Transm. Dis.* 26 (1999) 232-240.
- [121] C. Morgan-Davies, A. Waterhouse, C.E. Milne, A.W. Stott, Farmers' opinions on welfare, health and production practices in extensive hill sheep flocks in Great Britain, *Livest. Sci.* 104 (2006) 268-277.
- [122] B. Flatland, K.P. Freeman, L.M. Vap, K.E. Harr, ASVCP guidelines: quality assurance for point-of-care testing in veterinary medicine, *Vet. Clin. Pathol.* 42 (2013) 405-423.
- [123] B.T. Mitzner, It's time for in-house quality assurance, *J. Am. Anim. Hosp. Assoc.* 38 (2002) 12-13.
- [124] K.E. Blick, The essential role of information management in point-of-care/critical care testing, *Clin. Chim. Acta* 307 (2001) 159-168.
- [125] E.K. Sackmann, A.L. Fulton, D.J. Beebe, The present and future role of microfluidics in biomedical research, *Nature* 507 (2014) 181-189.
- [126] L. Ge, S. Wang, X. Song, S. Ge, J. Yu, 3D Origami-based multifunction-integrated immunodevice: low-cost and multiplexed sandwich chemiluminescence immunoassay on microfluidic paper-based analytical device, *Lab Chip* 12 (2012) 3150-3158.
- [127] S.S.Y. Wong, J.L.L. Teng, R.W.S. Poon, G.K.Y. Choi, K.H. Chan, M.L. Yeung, et al., Comparative Evaluation of a Point-of-Care Immunochromatographic Test SNAP 4Dx with Molecular Detection Tests for Vector-Borne Canine Pathogens in Hong Kong, *Vector-Borne Zoonotic Dis.* 11 (2011) 1269-1277.
- [128] C.G. Couto, L. Lorentzen, M.J. Beall, J. Shields, N. Bertolone, J.I. Couto, et al., Serological Study of Selected Vector-Borne Diseases in Shelter Dogs in Central Spain Using Point-of-Care Assays, *Vector-Borne Zoonotic Dis.* 10 (2010) 885-888.
- [129] M.C. Machen, S.G. Gordon, J.S. Buch, M.J. Beall, M.A. Oyama, Detection of occult feline cardiomyopathy using a pet-side point-of-care NT-PROBNP ELISA assay, *J. Vet. Intern. Med.* 26 (2012) 724-725.
- [130] K. Hartmann, R.M. Werner, H. Egberink, O. Jarrett, Comparison of six in-house tests for the rapid diagnosis of feline immunodeficiency and feline leukaemia virus infections, *Vet. Rec.* 149 (2001) 317-320.
- [131] P. Berdoulay, J.K. Levy, P.S. Snyder, M.J. Pegelow, J.L. Hooks, L.M. Tavares, et al., Comparison of serological tests for the detection of natural heartworm infection in cats, *J. Am. Anim. Hosp. Assoc.* 40 (2004) 376-384.
- [132] R.L. Seibert, K.M. Tobias, A. Reed, K.R. Snyder, Evaluation of a semiquantitative SNAP test for measurement of bile acids in dogs, *Peerj* 2 (2014) e539.
- [133] M.J. Beall, R. Cahill, K. Pigeon, J. Hanscom, S.P. Huth, Performance validation and method comparison of an in-clinic enzyme-linked immunosorbent assay for the detection of canine pancreatic lipase, *J. Vet. Diagn. Invest.* 23 (2011) 115-119.
- [134] E. Dewhurst, S. Cue, E. Crawford, K. Papasouliotis, A retrospective study of canine D-dimer concentrations measured using an immunometric "Point-of-Care" test, *J. Small Anim. Pract.* 49 (2008) 344-348.

- 669 [135] C.K. Chong, W. Jeong, H.Y. Kim, D.J. An, H.Y. Jeoung, J.E. Ryu, et al., Development and Clinical
 670 Evaluation of a Rapid Serodiagnostic Test for Toxoplasmosis of Cats Using Recombinant SAG1 Antigen,
 671 Korean J. Parasitol. 49 (2011) 207-212.
- 672 [136] K. Nielsen, W.L. Yu, L. Kelly, J. Williams, A. Dajer, E. Gutierrez, et al., Validation and field assessment of
 673 a rapid lateral flow assay for detection of bovine antibody to *Anaplasma marginale*, J. Immunoassay
 674 Immunochem. 30 (2009) 313-321.
- 675 [137] Y. Joon Tam, M.A. Mohd Lila, A.R. Bahaman, Development of solid - based paper strips for rapid
 676 diagnosis of Pseudorabies infection, Trop. biomed. 21 (2004) 121-134.
- 677 [138] T. Lin, J.J. Shao, J.Z. Du, G.Z. Cong, S.D. Gao, H.Y. Chang, Development of a serotype colloidal gold
 678 strip using monoclonal antibody for rapid detection type Asia1 foot-and-mouth disease, Virol. J. 8 (2011)
 679 418.
- 680 [139] S.M. Reid, N.P. Ferris, A. Bruning, G.H. Hutchings, Z. Kowalska, L. Akerblom, Development of a rapid
 681 chromatographic strip test for the pen-side detection of foot-and-mouth disease virus antigen, J. Virol.
 682 Methods 96 (2001) 189-202.
- 683 [140] S.Z. Yang, J.F. Yang, G.P. Zhang, S.L. Qiao, X.N. Wang, D. Zhao, et al., Development of a peptide-based
 684 immunochromatographic strip for differentiation of serotype O Foot-and-mouth disease virus-infected pigs
 685 from vaccinated pigs, J. Vet. Diagn. Invest. 22 (2010) 412-415.
- 686 [141] G.P. Zhang, Q.M. Li, Y.Y. Yan, J.Q. Guo, X.W. Li, R.G. Deng, et al., Development of a one-step strip test
 687 for the diagnosis of chicken infectious bursal disease, Avian Dis. 49 (2005) 177-181.
- 688 [142] J.K. McVicker, G.C. Rouse, M.A. Fowler, B.H. Perry, B.L. Miller, T.E. Johnson, Evaluation of a lateral-
 689 flow immunoassay for use in monitoring passive transfer of immunoglobulins in calves, Am. J. Vet. Res. 63
 690 (2002) 247-250.
- 691 [143] A. Bruening-Richardson, L. Akerblom, B. Klingeborn, J. Anderson, Improvement and development of
 692 rapid chromatographic strip-tests for the diagnosis of rinderpest and peste des petits ruminants viruses, J.
 693 Virol. Methods 174 (2011) 42-46.
- 694 [144] Y.S. Lyoo, S.B. Kleiboeker, K.-Y. Jang, N.K. Shin, J.-M. Kang, C.-H. Kim, et al., A Simple and Rapid
 695 Chromatographic Strip Test for Detection of Antibody to Porcine Reproductive and Respiratory Syndrome
 696 Virus, J. Vet. Diagn. Invest. 17 (2005) 469-473.
- 697 [145] M.P.A. Laitinen, M. Vuento, Immunochromatographic assay for quantitation of milk progesterone,
 698 Acta Chem. Scand. 50 (1996) 141-145.
- 699 [146] A. Bruning, K. Bellamy, D. Talbot, J. Anderson, A rapid chromatographic strip test for the pen-side
 700 diagnosis of rinderpest virus, J. Virol. Methods 81 (1999) 143-154.
- 701 [147] B.M. Buddle, T. Wilson, M. Denis, R. Greenwald, J. Esfandiari, K.P. Lyashchenko, et al., Sensitivity,
 702 Specificity, and Confounding Factors of Novel Serological Tests Used for the Rapid Diagnosis of Bovine
 703 Tuberculosis in Farmed Red Deer (*Cervus elaphus*), Clin. Vaccine Immunol. 17 (2010) 626-630.
- 704 [148] K.P. Lyashchenko, R. Greenwald, J. Esfandiari, M.A. Chambers, J. Vicente, C. Gortazar, et al., Animal-
 705 side serologic assay for rapid detection of *Mycobacterium bovis* infection in multiple species of free-ranging
 706 wildlife, Vet. Microbiol. 132 (2008) 283-292.
- 707 [149] K.P. Lyashchenko, R. Greenwald, J. Esfandiari, J.H. Olsen, R. Ball, G. Dumonceaux, et al., Tuberculosis
 708 in elephants: Antibody responses to defined antigens of *Mycobacterium tuberculosis*, potential for early
 709 diagnosis, and monitoring of treatment, Clin. Vaccine Immunol. 13 (2006) 722-732.
- 710 [150] M. Boadella, K. Lyashchenko, R. Greenwald, J. Esfandiari, R. Jaroso, T. Carta, et al., Serologic tests for
 711 detecting antibodies against *Mycobacterium bovis* and *Mycobacterium avium* subspecies *paratuberculosis*
 712 in Eurasian wild boar (*Sus scrofa scrofa*), J. Vet. Diagn. Invest. 23 (2011) 77-83.

- 713 [151] W.R. Waters, M.V. Palmer, T.C. Thacker, J.P. Bannantine, H.M. Vordermeier, R.G. Hewinson, et al.,
 714 Early antibody responses to experimental *Mycobacterium bovis* infection of cattle, Clin. Vaccine Immunol.
 715 13 (2006) 648-654.
- 716 [152] K.P. Lyashchenko, R. Greenwald, J. Esfandiari, D. Greenwald, C.A. Nacy, S. Gibson, et al., PrimaTB
 717 STAT-PAK Assay, a Novel, Rapid Lateral-Flow Test for Tuberculosis in Nonhuman Primates, Clin. Vaccine
 718 Immunol. 14 (2007) 1158-1164.
- 719 [153] C.F. Aldus, A. van Amerongen, R.M.C. Ariens, M.W. Peck, J.H. Wichers, G.M. Wyatt, Principles of some
 720 novel rapid dipstick methods for detection and characterization of verotoxigenic *Escherichia coli*, J. Appl.
 721 Microbiol. 95 (2003) 380-389.
- 722 [154] T.M. Huo, C.F. Peng, C.L. Xu, L.Q. Liu, Development of colloidal gold-based immunochromatographic
 723 assay for the rapid detection of medroxyprogesterone acetate residues, Food Agric. Immunol. 17 (2006)
 724 183-190.
- 725 [155] M. Pazzola, G. Piras, A. Noce, M.L. Dettori, G.M. Vacca, Evaluation of the rapid assay Betastar Combo
 726 3.0 for the detection of Penicillin, Amoxicillin, Cefazolin and Oxytetracycline in individual sheep milk, Small
 727 Ruminant Res. 124 (2015) 127-131.
- 728 [156] J. Kneebone, P.C.W. Tsang, D.H. Townson, Short communication: Rapid antibiotic screening tests
 729 detect antibiotic residues in powdered milk products, J. Dairy Sci. 93 (2010) 3961-3964.
- 730 [157] W. Reybroeck, S. Ooghe, H.F. De Brabander, E. Daeseleire, Validation of the β -s.t.a.r. 1+1 for rapid
 731 screening of residues of β -lactam antibiotics in milk, Food Addit. Contam. Part A - Chem. Anal. Control Expo.
 732 Risk Assess. 27 (2010) 1084-1095.
- 733 [158] M. O'Keeffe, P. Crabbe, M. Salden, J. Wichers, C. Van Peteghem, F. Kohen, et al., Preliminary
 734 evaluation of a lateral flow immunoassay device for screening urine samples for the presence of
 735 sulphamethazine, J. Immunol. Methods 278 (2003) 117-126.
- 736 [159] R. Verheijen, I.K. Osswald, R. Dietrich, W. Haasnoot, Development of a one step strip test for the
 737 detection of (dihydro)streptomycin residues in raw milk, Food Agric. Immunol. 12 (2000) 31-40.
- 738 [160] X.L. Wang, K. Li, D.S. Shi, N. Xiong, X. Jin, J.D. Yi, et al., Development of an immunochromatographic
 739 lateral-flow test strip for rapid detection of sulfonamides in eggs and chicken muscles, J. Agric. Food Chem.
 740 55 (2007) 2072-2078.
- 741 [161] E. Vidal, M. Marquez, A.J. Raeber, K. Meissner, B. Oesch, M. Pumarola, Applicability of a rapid
 742 chromatographic immunoassay for analysis of the distribution of PrPBSE in confirmed BSE cases, Vet. J. 177
 743 (2008) 448-451.
- 744 [162] G.P. Zhang, X.N. Wang, J.F. Yang, Y.Y. Yang, G.X. Xing, Q.M. Li, et al., Development of an
 745 immunochromatographic lateral flow test strip for detection of beta-adrenergic agonist Clenbuterol
 746 residues, J. Immunol. Methods 312 (2006) 27-33.
- 747 [163] J.R. Newgard, G.C. Rouse, J.K. McVicker, Novel method for detecting bovine immunoglobulin G in
 748 dried porcine plasma as an indicator of bovine plasma contamination, J. Agric. Food Chem. 50 (2002) 3094-
 749 3097.
- 750 [164] F. Sun, L. Liu, W. Ma, C. Xu, L. Wang, H. Kuang, Rapid on-site determination of melamine in raw milk
 751 by an immunochromatographic strip, Int. J. Food Sci. Tech. 47 (2012) 1505-1510.
- 752 [165] B.S. Delmulle, S. De Saeger, L. Sibanda, I. Barna-Vetro, C.H. Van Peteghem, Development of an
 753 immunoassay-based lateral flow dipstick for the rapid detection of aflatoxin B-1 in pig feed, J. Agric. Food
 754 Chem. 53 (2005) 3364-3368.
- 755 [166] A.Y. Kolosova, S. De Saeger, L. Sibanda, R. Verheijen, C. Van Peteghem, Development of a colloidal
 756 gold-based lateral-flow immunoassay for the rapid simultaneous detection of zearalenone and
 757 deoxynivalenol, Anal. Bioanal. Chem. 389 (2007) 2103-2107.

[167] K. Campbell, T. Fodey, J. Flint, C. Danks, M. Danaher, M. O'Keeffe, et al., Development and validation of a lateral flow device for the detection of nicarbazin contamination in poultry feeds, *J. Agric. Food Chem.* 55 (2007) 2497-2503.

[168] P. Moongkarndi, E. Rodpai, S. Kanarat, Evaluation of an immunochromatographic assay for rapid detection of *Salmonella enterica* serovars *Typhimurium* and *Enteritidis*, *J. Vet. Diagn. Invest.* 23 (2011) 797-801.

[169] G.P. Zhang, J.Q. Guo, X.N. Wang, J.X. Yang, Y.Y. Yang, Q.M. Li, et al., Development and evaluation of an immunochromatographic strip for trichinellosis detection, *Vet. Parasitol.* 137 (2006) 286-293.

[170] I. Patrascu, H.R. Gamble, L. Sofronic-Milosavljevic, R. Radulescu, A. Andrei, V. Ionescu, et al., The lateral flow card test: An alternative method for the detection of *Trichinella* infection in swine, *Parasite* 8 (2001) S240-S242.

Figure Legends

Fig. 1. Urine analysis performed using a dipstick test. The test strip is immersed in the urine sample for a few seconds, and, after a few minutes, the colour resulting from the reaction can be visually compared against the chromatic scale provided.

Fig. 2. Schematic representation of a lateral flow strip. A liquid sample is deposited on to the sample pad, migrating through a conjugate pad and a porous membrane for detection in a final absorbent pad. In most strip tests, the appearance of the control line indicates a valid test, while the appearance of a second test line indicates a positive test result.

Fig. 3. Stand-alone, self-powered integrated microfluidic blood analysis system (SIMBAS) [51]. The microfluidic platform integrates plasma separation from whole-blood with multiple immunoassays (A). Cross section of the device (B): fabrication materials (1); storage of the device in a vacuum package (2); addition of 5 ml of whole-blood sample on the inlet, degas-driven flow propels the sample into the device (3); blood cells sediment gravitationally and are filtered, while plasma flows into the channel (4); detection of multiple biomarkers (5); the flow is stopped by the suction chamber (6).

Fig. 4. 3D Origami-based microfluidic paper based analytical device [126]. Schematic representation, size and shape of the 3D origami-based device (A); the front and back surface of the device (B); binding of a

789 baked thin wax-patterned blotting paper on each waste tab, front (C) and back (D); binding of an unbaked
790 thick wax-patterned blotting paper on each waste tab (E, F). The assay procedure is carried out by folding
791 the different tabs above the test pad and adding the reagents sequentially, with the aid of a customised
792 device folder.

793

794

ACCEPTED MANUSCRIPT

Table 1. Examples of lateral flow immunoassays for POC diagnosis currently available for companion animals.

Disease/condition	Sample	Target analyte/pathogen	Target species	Commercial name	References
Addison's and Cushing disease	Serum	Cortisol	Dogs	SNAP® Cortisol Test	http://www.idexx.co.uk
Arthropod-borne diseases	Blood, serum or plasma	<i>Anaplasma phagocytophilum</i> and <i>platys</i> , <i>Ehrlichia canis</i> and <i>ewingii</i> , <i>Borrelia burgdorferi</i> , <i>Leishmania infantum</i> , <i>Dirofilaria immitis</i>	Cats and dogs	SNAP® 4Dx® Plus Test SNAP® 3Dx® Test SNAP Leishmania	[127, 128]
Cardiomyopathies	Serum or plasma	N-terminal pro-brain natriuretic peptide (NTproBNP)	Cats	SNAP® Feline proBNP Test	[129]
FIV and FeLV	Blood, serum or plasma	FIV and FeLV	Cats	BioSign® FeLV; BioSign® FIV; BioSign® FeLV/FIV; EVL One-step test; FASTest FeLV-FIV; SNAP® FIV/FeLV Combo Test; SNAP® Feline Triple® Test Speed Duo FELV/FIV; Witness FeLV-FIV	[130]
Giardiasis	Faeces	<i>Giardia</i>	Cats and dogs	SNAP® Giardia Test VetScan® Giardia Rapid Test	http://www.idexx.co.uk
Heartworm	Blood, serum or plasma	<i>Dirofilaria immitis</i>	Cats and dogs	BioSign® CHW; SNAP Feline Heartworm SNAP® Feline Triple® Test; WITNESS® DIROFILARIA	[131]
Liver disease	Serum	Bile acid	Cats and dogs	SNAP® Bile Acids Test	[132]
Lungworm	Serum or plasma	<i>Angiostrongylus vasorum</i>	Dogs	Angio Detect™ Test	http://www.idexx.co.uk
Pancreatitis	Serum	Pancreas-specific lipase	Cats and dogs	SNAP® fPL™ Test; SNAP® cPL™ Test	[133]
Parvovirus	Faeces	Parvovirus	Dogs	FASTest parvo strip; Witness parvo card; SAS™ Parvo; SNAP® Parvo Test; VetScan Canine Parvovirus Rapid Test; Speed® Parvo	[32]
Passive transfer of immunity	Blood, serum or plasma	IgG	Foals	SNAP® Foal IgG Test	http://www.idexx.co.uk
Thyroid disease	Serum or plasma	T4	Cats, dogs and horses	SNAP® Total T4 Test SNAP® T4 Test	http://www.idexx.co.uk
Thromboembolic disease	Citrated plasma	D-dimer	Dogs	NycoCard D-dimer test	[134]
Toxoplasmosis	Serum	<i>Toxoplasma gondii</i>	Cats	N/A	[135]

Table 2. Examples of lateral flow immunoassays for POC diagnosis currently available for livestock.

Disease/condition	Sample	Target analyte/pathogen	Target species	Commercial name	References
Anaplasmosis	Serum	<i>Anaplasma marginale</i>	Cattle	N/A	[136]
Aujeszky's Disease (Pseudorabies)	Serum	<i>Suid herpesvirus</i> type 1	Pigs	N/A	[137]
Bovine viral diarrhoea (BVD)	Serum and ear notch	Bovine viral diarrhoea virus (BVDV)	Cattle	SNAP® BVDV Test	http://www.idexx.co.uk
Classical Swine Fever	Blood	Classical swine fever virus	Pigs	CSFV Ab Test	http://www.idexx.co.uk
Foot and mouth disease (FMD)	Vesicular epithelium and fluid, blood	Foot and mouth disease virus	Ruminants and pigs	BioSign™ FMDV BioSign™ FMDV-Ag	[36, 138-140]
Infectious bursal disease	Bursa	Infectious bursal disease virus	Chickens	N/A	[141]
Neonatal diarrhoea	Faeces	Bovine rotavirus	Cattle	Rainbow Calf Scour Diagnostic Test	[33]
Passive transfer of immunity	Serum or plasma	IgG	Cattle	Midland quick test kit-calf IgG	[142]
Peste des petit ruminant	Lachrymal fluids	Peste des petit ruminant virus	Sheep and goats	N/A	[143]
Porcine reproductive and respiratory syndrome	Serum	Porcine reproductive and respiratory syndrome virus (PRRSV)	Pigs	BioSign® PRRSV	[12] [144]
Reproductive status	Milk	Progesterone	Cattle	N/A	[145]
Rinderpest	Lachrymal fluids	Rinderpest virus	Cattle	N/A	[146]
Tuberculosis	Blood, serum or plasma	<i>Mycobacterium bovis</i>	Red deer, wild boar, elephants, cattle and non-human primates	CervidTB STAT-PAK; VetTB STAT-PAK test; DPP® CervidTB; DPP® VetTB Assay for Elephants; PrimaTB STAT-PAK	[147-152]


Table 3. Examples of lateral flow immunoassays for POC diagnosis currently available for food safety.


Disease/condition	Sample	Target analyte/pathogen	Target species	Commercial name	References
Acute bloody diarrhoea	Milk	<i>Escherichia coli</i> O157:H7	Cattle	N/A	[153]
Anabolic steroid residues	Urine and liver	Medroxyprogesterone acetate (MPA)	Pigs	N/A	[154]
Antibiotic contamination	Milk, eggs, meat and urine	Beta-lactam, oxytetracycline, (dihydro)streptomycin gentamicin and sulfamethazine	Cattle, pigs, poultry, sheep and goats	Betastar® Combo Rapid Test; BioSign™ Sulfamethazine; Charm SL6™ Beta-lactam Test SNAP® Beta-Lactam ST Test; SNAPduo™ Beta-Tetra Test; SNAPduo™ Beta-Tetra Test ST; SNAP® Gentamicin Test; SNAP® MRL Test; SNAP® NBL Test; SNAP® Tetracycline Test; SNAP® Sulphamethazine Test	[155-160]
BSE	Brain	PrPBSE	Cattle	Prionics-Check PrioSTRIP	[161]
Clenbuterol contamination	Urine	Clenbuterol	Pigs	N/A	[162]
Mammalian proteins contamination of feed stuff	Plasma	Bovine IgG	Cattle	N/A	[163]
Melamime	Milk	Melamime	Cattle	SNAP® Melamine Test	[164]
Mycotoxins contamination	Feed matrix and milk	Aflatoxin B1 and M1, deoxynivalenol and zearalenone	Cattle and pigs	SNAP® AFM1 Test ROSA Mycotoxin Strips	[165, 166]
Nicarbazin residues	Feed matrix	Nicarbazin	Poultry	N/A	[167]
Salmonellosis	Meat	<i>Salmonella typhimurium</i> and <i>enteritidis</i>	Poultry	N/A	[168]
Trichinellosis	Blood, serum and meat	<i>Trichinella spiralis</i>	Pigs	N/A	[169], [170]


Table 4. Examples of commercially available microfluidic-based POC technologies for human diagnostic applications.


Diagnostic application	Time to results	Sample type	Technology	Commercial name	Company homepage
Blood analysis (blood gas, electrolyte, haematology and metabolite panel)	30 seconds	Whole blood (100µl)	Test-card with card reader	epoc BGEM™	http://epocal.com
	2 minutes	Whole blood (2-3 drops)	Test cartridge with handheld analyser	i-STAT	https://www.abbottpointofcare.com
Blood typing	Few minutes	Fingerprick blood sample	Disposable, credit card sized microfluidic device	ABORhCard®	http://www.micronics.net [155-160][155-160][157-162]
Cardiac Troponin-I assay	10 minutes	Fingerprick blood sample	Integrated, self-contained assay cartridge with handheld reader	Nanōmix eLab	http://nano.com
Cancer diagnosis	100 minutes	Plasma (1ml)	Test cartridge with platform	Idylla™ ctBRAF Mutation assay	https://www.biocartis.com
Coagulation monitoring (Prothrombin Time test)	3 minutes	Whole blood (5µl)	Memory microchip with a meter	CoagMax®	http://www.microvisk.com
Fertility (FSH, LH, PL)	30 minutes	Serum (20µl)	Test cartridge with reader	Acix 100	http://www.achiralabs.com
Gastrointestinal infection (<i>Clostridium</i>)	Less than 2 hours	Stool	Test cartridge with reader	Verigene® C.	http://www.nanosphere.us

<i>difficile</i>) HIV	50 minutes	Whole blood or plasma (100µl)	Test cartridge with analyzer unit	<i>difficile</i> Test (CDF) EOSCAPE-HIV	http://www.wave80.com
Inflammation (C-reactive protein)	Few minutes	Whole blood, serum or plasma (5µl)	DVD-like disc with reading instrument	spinit [®] CRP	http://biosurfit.com
Lithium levels (bipolar disorder)	Few minutes	Fingerprick blood sample	Disposable lab-chip with a meter	Medimate MiniLab	https://www.medimate.com
Prostate Specific Antigen (PSA)	3 minutes	Serum or plasma (30µl)	Disposable cartridge with analyzing instrument	FREND™ PSA plus	http://nanoentek.com
Septicaemia	2-3 hours	Whole blood (10ml)	USB size chip with purpose-designed platform	Genalysis [®]	http://www.dnae.com/index.html









- Current state of the art for point-of-care testing in veterinary medicine
- Animal diseases where point-of-care tests are of particular importance
- Possible future application of emerging microfluidic technologies in veterinary diagnostics

Professor Xinyu Liu

Rm 155, Macdonald Engineering Building

Faculty of Engineering, McGill University

Montreal, Quebec, H3A 0C3, Canada

Tel: 514-398-1526

E-mail: Xinyu.liu@mcgill.ca

Professor Jack Luo

Institute for Materials Research and Innovation

The University of Bolton

Deane Road, Bolton, BL3 5AB, UK

Tel: +44 (0)1204 903523

Fax: +44 (0)1204 399074

E-mail: J.Luo@bolton.ac.uk

Dr Stewart Smith

Scottish Microelectronics Centre

School of Engineering, Kings buildings

The University of Edinburgh

Edinburgh, EH9 3JF, UK

Tel: +44(0)131 6507471

E-mail: Stewart.Smith@ed.ac.uk

Professor Richard Wall

Office Life Sciences: 2A02, School of biological science, Life Sciences Building

24 Tyndall Avenue, Bristol BS8 1TQ

Tel: +44 (0) 117 39 41205

E-mail: richard.wall@bristol.ac.uk

Professor Enrico Bollo

Dipartimento di Scienze Veterinarie

Largo Paolo Braccini 2

10095 Grugliasco (TO) – Italia

Tel: (+39) 0116709036

E-mail: enrico.bollo@unito.it